Hjem › Prostatakreft › Virginia › Charlottesville
Kliniske studier for Prostatakreft i Charlottesville, VA
15 studier for Prostatakreft søker deltakere på steder i og rundt Charlottesville (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
RekruttererFase 3
- University of Virginia Health System ( Site 0054), Charlottesville
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
RekruttererFase 3
- University of Virginia Comprehensive Cancer Center, Charlottesville
- University of Virginia, Charlottesville
- UVA Health Cancer Care Pantops, Charlottesville
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
RekruttererFase 3
- University of Virginia Cancer Center, Charlottesville
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
RekruttererFase 2
- University of Virginia Cancer Center, Charlottesville
The Vanguard Study: Testing a New Way to Screen for Cancer
RekruttererFrivillige helsepersonell ønskes velkommen
- Sentara Martha Jefferson Hospital, Charlottesville
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
RekruttererFase 3
- University of Virginia Cancer Center, Charlottesville
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
RekruttererFase 2
- University of Virginia Comprehensive Cancer Center, Charlottesville
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RekruttererFase 1/2
- University of Virginia, Charlottesville
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
RekruttererFase 3
- University of Virginia Cancer Center, Charlottesville
HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)
RekruttererFase 1/2
- University of Virginia, Charlottesville
A Feasibility Study of Biometric Measurements Via Wearable Smart Watch Technology for Evaluation of Vasomotor Symptoms in Patients Treated With Androgen Deprivation Therapy for Prostate Cancer (Prostate 007)
Rekrutterer
- University of Virginia Health System, Charlottesville
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
RekruttererObservasjonsstudie
- University of Virginia, Charlottesville
Remotely Monitored Exercise Interventions in Patients With mCSPC Undergoing ADT (Prostate 006)
Rekrutterer
- University of Virginia, Charlottesville
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
RekruttererFase 1
- University of Virginia Cancer Center, Charlottesville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, Charlottesville
Prostatakreft-studier i andre byer
- New York City, NY103 studier
- Houston, TX76 studier
- Los Angeles, CA61 studier
- Boston, MA59 studier
- St. Louis, MO46 studier
- Chicago, IL45 studier
- San Francisco, CA45 studier
- Philadelphia, PA44 studier
- Baltimore, MD43 studier
- Nashville, TN42 studier
- Seattle, WA42 studier
- Washington, DC38 studier
Andre studier i Charlottesville
- Ikke-småcellet lungekreft21 studier
- Akut myelogen leukemi16 studier
- Metastatisk kreft13 studier
- Endometriekreft13 studier
- Kreft (alle typer)13 studier
- Lungekreft13 studier
- Hjertesvikt11 studier
- Eggstokkreft10 studier
- Kolorektal kreft10 studier
- Type 1-diabetes9 studier
- Brystkreft9 studier
- Pankreaskreft9 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.